Примери за използване на Booster dose на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Month after booster Dose.
Booster dose(Children and adolescents).
A booster dose must be given.
Of these, 76, 96 and 49 infants, respectively,received a booster dose.
Booster dose at 9-10 months of age.
They then received a booster dose shortly after their first birthday.
Booster dose at 9-12 versus 15-18 months of age.
Your doctor will advise you if andwhen you should receive a booster dose.
Booster dose 12 months after primary immunization N= 149.
There is limited experience for the booster dose in the elderly population.
Booster dose should be given in accordance with the official recommendations.
After a 2-dose primary vaccination with Hexyon, a booster dose must be given.
Responses to the booster dose administered at 12 months were unaffected.
Some local vaccination schedules currently include recommendations for a booster dose.
A booster dose is recommended before the end of the second year of life.
Forty-two days after the booster dose, the seroprotection rate against.
A booster dose elicited an anamnestic response indicative of an immune memory.
Children from 14 months to< 3 years of age should receive a single 0.25 ml booster dose.
A booster dose should be given when antibody levels decline below 10 IU/l.
This vaccination is carried out three times,then a booster dose is recommended every three years.
A booster dose of Fendrix may be given, according to official recommendations.
The study also looked at the effect of a booster dose given after twelve months in some of the children.
A booster dose should be given at least six months after the last of these initial doses. .
In the absence of hepatitisB vaccination at birth, it is necessary to give a hepatitis B vaccine booster dose.
It is recommended that a booster dose be given at least 6 months after the third dose. .
Children aged 7-11 months received 2 primary doses followed by a booster dose in the second year of life.
Other vaccines, the booster dose is potentially associated with an increased incidence of minor adverse.
The incidence of fever following co-administration of the two vaccines in the primary series was lower than that observed after the booster dose.
The immunogenicity of a booster dose at 18 to 24 months of age was evaluated in approximately 200 preterm infants.